Atlas Trials

Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer

Clinical trial NCT06722911 · RECRUITING

Trial details

NCT number
NCT06722911
Sponsor
Zhejiang Provincial People's Hospital
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Pancreatic Cancer Resectable
Start date
2024-11-15
Primary completion
2028-09-30
Enrollment
57

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.